论文部分内容阅读
为了探讨食管癌放疗前后血清ＴＧＦβ１ 水平改变与放疗疗效及预后的关系，采用免疫酶联方法对３０ 例明确诊断的食管癌患者放疗前后血清ＴＧＦβ１ 水平进行检测，并对其改变与病变长度、部位、Ｘ 线分型、近期疗效及转移复发的关系进行对比分析。结果表明放疗前食管癌患者血清ＴＧＦβ１ 平均水平明显高于对照组，差异非常显著（Ｐ＜ ０．０１），放疗后血清ＴＧＦβ１ 水平改变与病变长度、部位、Ｘ线分型无关（ Ｐ＞０ ．０５） ，与近期疗效及转移复发密切相关（Ｐ＜ ０．０１）。认为血清ＴＧＦβ１ 水平可以作为监测食管癌放疗疗效和预后的一项重要指标。
To investigate the relationship between changes of serum TGFβ1 level and radiotherapy efficacy and prognosis before and after radiotherapy for esophageal cancer, the serum levels of TGFβ1 in 30 esophageal cancer patients diagnosed before and after radiotherapy were detected by immunoenzyme-linked immunosorbent assay. The X-ray classification, the short-term efficacy and the relationship between metastasis and recurrence were compared. The results showed that the average serum TGFβ1 level in patients with esophageal cancer before radiotherapy was significantly higher than that in the control group (P<0.01). The change of serum TGFβ1 level after radiotherapy was not associated with lesion length, location, and X-ray classification (P>0). 05) is closely related to the short-term efficacy, metastasis and recurrence (P < 0.01). It is considered that serum TGFβ1 level can be used as an important indicator to monitor the efficacy and prognosis of esophageal cancer radiotherapy.